or Try an Advanced Search...

    Enzyme Replacement Therapy Stocks List

    Symbol Grade Name % Change
    RARE D Ultragenyx Pharmaceutical Inc. 0.53
    FOLD D Amicus Therapeutics, Inc. -0.38
    BMRN F BioMarin Pharmaceutical Inc. -1.40
    PLX F Protalix BioTherapeutics, Inc. -1.72
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Rare Diseases Biotechnology Fabry Disease Gaucher Disease Inborn Errors Of Metabolism Life Sciences Lysosomal Storage Disorder Medicine Mucopolysaccharidosis Pompe Disease Achondroplasia Acid Autoimmune Disease Autoimmune Disorders Biodefense Biologics Biology Cancer Choline

    Related ETFs - A few ETFs which own one or more of the above listed Enzyme Replacement Therapy stocks.

    Symbol Grade Name Weight
    GNOM D Global X Genomics & Biotechnology ETF 8.67
    PBE C PowerShares Dynamic Biotech & Genome 7.66
    BBP C BioShares Biotechnology Products Fund 5.5
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 4.76
    TMFM A Motley Fool Mid-Cap Growth ETF 4.17
    View all Enzyme Replacement Therapy ETFs...
    Compare ETFs
    Compare BBP to TMFM Compare GNOM to PBE Compare PBE to BBP

        Enzyme Replacement Therapy Stocks Recent News

        Date Stock Title
        May 3 FOLD ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
        May 3 PLX Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
        May 3 RARE Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
        May 2 RARE Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
        May 2 RARE Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64M
        May 2 RARE Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
        May 1 RARE Ultragenyx Pharmaceutical Q1 2024 Earnings Preview
        May 1 FOLD Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
        May 1 FOLD Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
        Apr 30 RARE Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
        Apr 30 RARE Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
        Apr 30 BMRN BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
        Apr 29 BMRN BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says
        Apr 27 BMRN 4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
        Apr 27 BMRN Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Rare Diseases Biotechnology Fabry Disease Gaucher Disease Inborn Errors Of Metabolism Life Sciences Lysosomal Storage Disorder Medicine Mucopolysaccharidosis Pompe Disease Achondroplasia Acid Autoimmune Disease Autoimmune Disorders Biodefense Biologics Biology Cancer Choline
        Enzyme Replacement Therapy

        Enzyme replacement therapy (ERT) is a type of medical treatment used to replace enzymes that are missing or not working properly in the body. It is used to treat a variety of genetic disorders, including lysosomal storage diseases, such as Gaucher disease, Fabry disease, and Pompe disease. ERT involves the intravenous administration of a recombinant enzyme, which is a laboratory-made version of the enzyme that is missing or not working properly in the body. The enzyme helps to break down substances that would otherwise accumulate in the body, leading to symptoms and complications.

        Browse All Tags